Do you want to read an article? Please log in or register.
Use of inhaled corticosteroids and risk of acquiring Pseudomonas aeruginosa in patients with chronic obstructive pulmonary disease
COPDPneumoniaRespiratory Tract Infection
RECOMMENDED
Related content
COPD
Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study
Respiration.
Rodrigo-Troyano A, Melo V, Marcos PJ, Laserna E, Peiro M, Suarez-Cuartin G, Perea L, Feliu A, Plaza V, Faverio P, Restrepo MI, Anzueto A, Sibila O
doi: 10.1159/000490190.
AsthmaCOPD
Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials
Lancet Respir Med.
Bafadhel M, Peterson S, De Blas MA, Calverley PM, Rennard SI, Richter K, Fagerås M
doi: 10.1016/
COPD
Assessing the healthcare resource use associated with inappropriate prescribing of inhaled corticosteroids for people with chronic obstructive pulmonary disease (COPD) in GOLD groups A or B: an observational study using the Clinical Practice Research Datalink (CPRD)
Respir Res.
Chalmers JD, Poole C, Webster S, Tebboth A, Dickinson S, Gayle A
doi: 10.1186/s12931-018-0767-2.
RECOMMENDED
AsthmaCOPD
Risk of COVID-19-related death among patients with chronic obstructive pulmonary disease or asthma prescribed inhaled corticosteroids: an observational cohort study using the OpenSAFELY platform
★ 3
Recommended by
Dr Martin Frey, Faculty Member
★ 2
Recommended by
Dr Marcus Hesse, Faculty Member
Lancet Respir Med.
Schultze A, Walker AJ, MacKenna B, Morton CE, Bhaskaran K, Brown JP, Rentsch CT, Williamson E, Drysdale H, Croker R, Bacon S, Hulme W, Bates C, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, Tomlinson L, Mathur R, Wing K, Wong AYS, Forbes H, Parry J, Hester F, Harper S, Evans SJW, Quint J, Smeeth L, Douglas IJ, Goldacre B, OpenSAFELY Collaborative.
doi: 10.1016/S2213-2600(20)30415-X.
RECOMMENDED
COPD
Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic Obstructive Pulmonary Disease
J Am Coll Cardiol.
Adamson PD, Anderson JA, Brook RD, Calverley PMA, Celli BR, Cowans NJ, Crim C, Dixon IJ, Martinez FJ, Newby DE, Vestbo J, Yates JC, Mills NL
doi: 10.1016/j.jacc.2018.06.051.
COMMENTED
COPD
Alignment of Inhaled Chronic Obstructive Pulmonary Disease Therapies with Published Strategies. Analysis of the Global Initiative for Chronic Obstructive Lung Disease Recommendations in SPIROMICS
Ann Am Thorac Soc.
Ghosh S, Anderson WH, Putcha N, Han MK, Curtis JL, Criner GJ, Dransfield MT, Barr RG, Krishnan JA, Lazarus SC, Cooper CB, Paine R 3rd, Peters SP, Hansel NN, Martinez FJ, Drummond MB, Current and former investigators of the SPIROMICS sites and reading centers
doi: 10.1513/AnnalsATS.201804-283OC.
RECOMMENDED
COPD
Inhaled Corticosteroids in Chronic Obstructive Pulmonary Disease: Benefits and Risks
★ 1
Recommended by
Dr Martin Frey, Faculty Member
Clin Chest Med.
Mkorombindo T, Dransfield MT
doi: 10.1016/j.ccm.2020.05.006.
RECOMMENDED
Lung Cancer
Inhaled corticosteroids and the risk of lung cancer in chronic obstructive pulmonary disease (COPD): a population-based cohort study
Eur Respir J.
Raymakers AJN, Sadatsafavi M, Sin DD, FitzGerald JM, Marra CA, Lynd LD
doi: 10.1183/13993003.
RECOMMENDED
COPD
Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta2-agonists formulations in chronic obstructive pulmonary disease
Respir Med.
Pirina P, Foschino Barbaro MP, Paleari D, Spanevello A
doi: 10.1016/j.rmed.2018.08.013.